Orion Pragmatic After First-Quarter COVID-19 Impact
As Profit Jumps More Than Half Year-Over-Year
Buoyed by strong demand caused by COVID-19 induced stockpiling, including for its range of generic products, Finland’s Orion enjoyed double-digit growth in the first quarter. However, this trend will ease off through the year, the company says.
You may also be interested in...
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.